IntrinsiChem
Consulting Inc.

I was drawn to science at a very early age. While spending the summer working in a chemistry lab as an undergraduate, I became fascinated at the thought that I could mix chemicals together and make a molecule that no one else in the world had ever made! Since that moment, I have spent my career studying the interface between chemistry and biology, hunting for molecules and therapies that will benefit patients. 

 

I have over 20 years of drug development experience including discovery chemistry, CMC regulatory affairs and IP portfolio management. I launched IntrinsiChem Consulting in 2021 at the height of the pandemic. With one of my recent clients, GeneTether Inc., a firm focused on developing a CRISPR-based platform for the treatment of rare monogenic diseases, I worked closely with the CSO and CEO to develop research and development strategies as well as working with outside counsel to draft the scientific business section of their preliminary prospectus for which they closed a successful IPO on the Canadian Securities Exchange in March 2022.

 

Prior to forming IntrinsiChem, I served as the Director of Research and Development at Scientus Pharma and led the advancement of their extraction technology through to commercialization. I spent 10 years as a Scientist in the Therapeutics Group at the University Health Network (UHN) where I was involved in discovery research and led the CMC development programs for three clinical candidates. I have also held various R&D leadership roles of increasing responsibility at Affinium Pharmaceuticals Inc., GlycoDesign Inc., and Albany Molecular Research Inc. (currently Curia Inc.).

 

I hold a BSc (Hons) in Chemistry from St. Mary’s University and MSc and PhD degrees in Organic Chemistry from the University of Waterloo. I have had the privilege of working with many great scientists that has enabled me to be the co-author and inventor on over 40 peer-reviewed publications and patents.